AZN May 2024 65.000 put

OPR - OPR Delayed price. Currency in USD

Add to watchlist

0.4000

0.0000

(0.00%)

At close: 10:15AM EDT

Loading interactive chart…

Zacks
Pharma Stock Roundup: AZN's 2030 Sales Target, PFE's New Cost Cut Plan & More
AstraZeneca (AZN) announces an ambitious target of achieving $80 billion in revenues by 2030. Pfizer (PFE) announces a multi-year, multi-phase cost reduction program.
Simply Wall St.
Here's Why We Think AstraZeneca (LON:AZN) Is Well Worth Watching
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
Business Wire
AstraZeneca demonstrates commitment to patients living with amyloidosis at the 2024 International Symposium on Amyloidosis (ISA)
WILMINGTON, Del., May 23, 2024--AstraZeneca and Alexion, AstraZeneca Rare Disease, will showcase 14 studies, including real-world evidence (RWE), from their portfolio and pipeline of investigational amyloidosis therapies at the International Symposium on Amyloidosis (ISA), in Rochester, MN from May 26–30, 2024.